{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T05:50:10Z","timestamp":1794030610003,"version":"4.8.0"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.metabol.2026.156682","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T23:34:21Z","timestamp":1782171261000},"page":"156682","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["A translational model of MASLD-associated HFpEF defines mitochondrial dysfunction and cardiac plasticity during disease progression and regression"],"prefix":"10.1016","volume":"182","author":[{"given":"Souradipta","family":"Ganguly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betul","family":"Gunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusu","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Suarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautam","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Ishizuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rabi","family":"Murad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Kisseleva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Dillmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirk","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Adler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Brenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debanjan","family":"Dhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.metabol.2026.156682_bb0005","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12196216","article-title":"Metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: the patient and physician perspective","volume":"12","author":"Eskridge","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.metabol.2026.156682_bb0010","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.54707","article-title":"Estimated burden of metabolic dysfunction-associated steatotic liver disease in US adults, 2020 to 2050","volume":"8","author":"Le","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.metabol.2026.156682_bb0015","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S2213-8587(24)00318-8","article-title":"Metabolic dysfunction-associated steatotic liver disease: heterogeneous pathomechanisms and effectiveness of metabolism-based treatment","volume":"13","author":"Stefan","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.metabol.2026.156682_bb0020","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","article-title":"Mechanisms and disease consequences of nonalcoholic fatty liver disease","volume":"184","author":"Loomba","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.metabol.2026.156682_bb0025","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.jhep.2008.06.018","article-title":"Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease","volume":"49","author":"Ong","year":"2008","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2026.156682_bb0030","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s12072-023-10543-8","article-title":"An international multidisciplinary consensus statement on MAFLD and the risk of CVD","volume":"17","author":"Zhou","year":"2023","journal-title":"Hepatol Int"},{"key":"10.1016\/j.metabol.2026.156682_bb0035","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1136\/gutjnl-2021-325724","article-title":"Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort","volume":"71","author":"Simon","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.metabol.2026.156682_bb0040","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1136\/gutjnl-2023-330595","article-title":"MASLD: a systemic metabolic disorder with cardiovascular and malignant complications","volume":"73","author":"Targher","year":"2024","journal-title":"Gut"},{"key":"10.1016\/j.metabol.2026.156682_bb0045","doi-asserted-by":"crossref","first-page":"3624","DOI":"10.1038\/s41591-024-03283-1","article-title":"Data-driven cluster analysis identifies distinct types of metabolic dysfunction-associated steatotic liver disease","volume":"30","author":"Raverdy","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.metabol.2026.156682_bb0050","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13195901","article-title":"Novel biomarkers of grade I left ventricular diastolic dysfunction in type 2 diabetes patients with metabolic-dysfunction-associated steatotic liver disease","volume":"13","author":"Braha","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.metabol.2026.156682_bb0055","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1016\/j.jacc.2023.01.049","article-title":"Heart failure with preserved ejection fraction: JACC scientific statement","volume":"81","author":"Borlaug","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.metabol.2026.156682_bb0060","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.935390","article-title":"Association of metabolic dysfunction-associated fatty liver disease with left ventricular diastolic function and cardiac morphology","volume":"13","author":"Peng","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.metabol.2026.156682_bb0065","doi-asserted-by":"crossref","DOI":"10.4330\/wjc.v18.i1.111954","article-title":"Metabolic dysfunction-associated steatotic liver disease and heart failure with preserved ejection fraction: a state-of-the-art review","volume":"18","author":"Brar","year":"2026","journal-title":"World J Cardiol"},{"key":"10.1016\/j.metabol.2026.156682_bb0070","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.014279","article-title":"Longitudinal association of non-alcoholic fatty liver disease with changes in myocardial structure and function: the CARDIA study","volume":"9","author":"VanWagner","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.metabol.2026.156682_bb0075","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1038\/s44161-025-00754-7","article-title":"Modeling HFpEF in animals","volume":"4","author":"Kass","year":"2025","journal-title":"Nat Cardiovasc Res"},{"key":"10.1016\/j.metabol.2026.156682_bb0080","doi-asserted-by":"crossref","first-page":"4420","DOI":"10.1093\/eurheartj\/ehab389","article-title":"Heart failure with preserved ejection fraction in humans and mice: embracing clinical complexity in mouse models","volume":"42","author":"Withaar","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.metabol.2026.156682_bb0085","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.jcmgh.2021.05.010","article-title":"Nonalcoholic steatohepatitis and HCC in a hyperphagic mouse accelerated by Western diet","volume":"12","author":"Ganguly","year":"2021","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2026.156682_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.156028","article-title":"The role of dietary modification in the prevention and management of metabolic dysfunction-associated fatty liver disease: an international multidisciplinary expert consensus","volume":"161","author":"Zeng","year":"2024","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2026.156682_bb0095","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2405746121","article-title":"Lipid-associated macrophages\u2019 promotion of fibrosis resolution during MASH regression requires TREM2","volume":"121","author":"Ganguly","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.metabol.2026.156682_bb0100","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1159\/000508636","article-title":"Western diet promotes renal injury, inflammation, and fibrosis in a murine model of Alstrom syndrome","volume":"144","author":"Kim","year":"2020","journal-title":"Nephron"},{"key":"10.1016\/j.metabol.2026.156682_bb0105","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1210\/me.2005-0494","article-title":"Fat Aussie\u2014a new Alstr\u00f6m syndrome mouse showing a critical role for ALMS1 in obesity, diabetes, and spermatogenesis","volume":"20","author":"Arsov","year":"2006","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.metabol.2026.156682_bb0110","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.jhep.2017.01.022","article-title":"NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice","volume":"66","author":"Mridha","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2026.156682_bb0115","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/nm.4346","article-title":"Thermoneutral housing exacerbates nonalcoholic fatty liver disease in mice and allows for sex-independent disease modeling","volume":"23","author":"Giles","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.metabol.2026.156682_bb0120","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1161\/01.RES.0000102042.83024.CA","article-title":"What is the role of beta-adrenergic signaling in heart failure?","volume":"93","author":"Lohse","year":"2003","journal-title":"Circ Res"},{"key":"10.1016\/j.metabol.2026.156682_bb0125","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1161\/CIRCRESAHA.113.300308","article-title":"Adrenergic nervous system in heart failure: pathophysiology and therapy","volume":"113","author":"Lymperopoulos","year":"2013","journal-title":"Circ Res"},{"key":"10.1016\/j.metabol.2026.156682_bb0130","first-page":"I82","article-title":"Beta-adrenergic inotropic responsiveness of patients with heart failure: studies with intracoronary dobutamine infusion","volume":"61","author":"Colucci","year":"1987","journal-title":"Circ Res"},{"key":"10.1016\/j.metabol.2026.156682_bb0135","article-title":"Cirrhotic cardiomyopathy: the interplay between liver and heart","volume":"14","author":"Kalluru","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.metabol.2026.156682_bb0140","doi-asserted-by":"crossref","DOI":"10.3389\/fnetp.2022.849253","article-title":"Pathogenic mechanisms underlying cirrhotic cardiomyopathy","volume":"2","author":"Liu","year":"2022","journal-title":"Front Netw Physiol"},{"key":"10.1016\/j.metabol.2026.156682_bb0145","first-page":"1893","article-title":"The role of BNP testing in heart failure","volume":"74","author":"Doust","year":"2006","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.metabol.2026.156682_bb0150","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41569-024-01067-1","article-title":"Pathophysiological insights into HFpEF from studies of human cardiac tissue","volume":"22","author":"Fayyaz","year":"2025","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.metabol.2026.156682_bb0155","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11082131","article-title":"Myocardial RNA sequencing reveals new potential therapeutic targets in heart failure with preserved ejection fraction","volume":"11","author":"Inacio","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.metabol.2026.156682_bb0160","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s11886-024-02185-5","article-title":"Cardiovascular risk reduction in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis","volume":"27","author":"Bernhard","year":"2025","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.metabol.2026.156682_bb0165","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1111\/bph.15530","article-title":"Constitutive protein kinase G activation exacerbates stress-induced cardiomyopathy","volume":"179","author":"Schwaerzer","year":"2022","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.metabol.2026.156682_bb0170","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1161\/CIRCULATIONAHA.114.009625","article-title":"Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction","volume":"131","author":"Mohammed","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.metabol.2026.156682_bb0175","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1016\/j.bbadis.2013.07.023","article-title":"Regulation of fetal gene expression in heart failure","volume":"1832","author":"Dirkx","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.metabol.2026.156682_bb0180","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0022-5223(19)37950-4","article-title":"Ultrastructural and cytochemical correlates of myocardial protection by cardiac hypothermia in man","volume":"79","author":"Flameng","year":"1980","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.metabol.2026.156682_bb0185","doi-asserted-by":"crossref","first-page":"H965","DOI":"10.1152\/ajpheart.00202.2023","article-title":"Three-dimensional mitochondria reconstructions of murine cardiac muscle changes in size across aging","volume":"325","author":"Vue","year":"2023","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.metabol.2026.156682_bb0190","doi-asserted-by":"crossref","DOI":"10.15190\/d.2017.1","article-title":"Unique morphological characteristics of mitochondrial subtypes in the heart: the effect of ischemia and ischemic preconditioning","volume":"5","author":"Kalkhoran","year":"2017","journal-title":"Discoveries (Craiova)"},{"key":"10.1016\/j.metabol.2026.156682_bb0195","doi-asserted-by":"crossref","DOI":"10.1038\/s41569-026-01257-z","article-title":"HFpEF and MASLD: converging mechanisms and clinical implications","author":"Capone","year":"2026","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.metabol.2026.156682_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154707","article-title":"Elafibranor improves diet-induced nonalcoholic steatohepatitis associated with heart failure with preserved ejection fraction in Golden Syrian hamsters","volume":"117","author":"Briand","year":"2021","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2026.156682_bb0205","doi-asserted-by":"crossref","first-page":"439","DOI":"10.5551\/jat.40956","article-title":"A high-fat and high-cholesterol diet induces cardiac fibrosis, vascular endothelial, and left ventricular diastolic dysfunction in SHRSP5\/Dmcr rats","volume":"25","author":"Watanabe","year":"2018","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.metabol.2026.156682_bb0210","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0339642","article-title":"Diet-induced steatohepatitis does not cause heart failure with preserved ejection fraction in male middle-aged C57BL\/6N mice","volume":"20","author":"Kessinger","year":"2025","journal-title":"PloS One"},{"key":"10.1016\/j.metabol.2026.156682_bb0215","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1126\/science.adl4100","article-title":"Bile acid synthesis impedes tumor-specific T cell responses during liver cancer","volume":"387","author":"Varanasi","year":"2025","journal-title":"Science"},{"key":"10.1016\/j.metabol.2026.156682_bb0220","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/s41586-024-08317-9","article-title":"FBP1 controls liver cancer evolution from senescent MASH hepatocytes","volume":"637","author":"Gu","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.metabol.2026.156682_bb0225","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease","volume":"149","author":"Angulo","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.metabol.2026.156682_bb0230","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.cgh.2022.04.014","article-title":"Mortality outcomes by fibrosis stage in nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"21","author":"Ng","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2026.156682_bb0235","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1056\/NEJMcp2305181","article-title":"Heart failure with preserved ejection fraction","volume":"392","author":"Cannata","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2026.156682_bb0240","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/s41586-019-1100-z","article-title":"Nitrosative stress drives heart failure with preserved ejection fraction","volume":"568","author":"Schiattarella","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.metabol.2026.156682_bb0245","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1161\/CIRCRESAHA.120.317046","article-title":"NAD(+) repletion reverses heart failure with preserved ejection fraction","volume":"128","author":"Tong","year":"2021","journal-title":"Circ Res"},{"key":"10.1016\/j.metabol.2026.156682_bb0250","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1161\/CIRCULATIONAHA.122.061846","article-title":"Myocardial metabolomics of human heart failure with preserved ejection fraction","volume":"147","author":"Hahn","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.metabol.2026.156682_bb0255","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1161\/CIRCULATIONAHA.119.043450","article-title":"Cardiac energetics in patients with aortic stenosis and preserved versus reduced ejection fraction","volume":"141","author":"Peterzan","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.metabol.2026.156682_bb0260","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10112943","article-title":"Unveiling human proteome signatures of heart failure with preserved ejection fraction","volume":"10","author":"Sebastiao","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.metabol.2026.156682_bb0265","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1161\/CIRCULATIONAHA.124.070535","article-title":"Cardiovascular-liver-metabolic health: recommendations in screening, diagnosis, and management of metabolic dysfunction-associated steatotic liver disease in cardiovascular disease via modified Delphi approach","volume":"151","author":"Chew","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.metabol.2026.156682_bb0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2026.156494","article-title":"Emerging incretin- and multi-agonist-based treatments - the continued refinement and continuous expansion of a potent therapeutic armamentarium for cardio-kidney-liver-metabolic diseases and beyond","volume":"177","author":"Muzurovic","year":"2026","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2026.156682_bb0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.155997","article-title":"Management of patients with the cardio renal liver metabolic syndrome: the need for a multidisciplinary approach in research, education and practice","volume":"159","author":"Angelidi","year":"2024","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2026.156682_bb0280","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S2468-1253(25)00323-1","article-title":"Pharmacotherapy for metabolic dysfunction-associated steatohepatitis: heart-liver co-management","volume":"11","author":"Zhou","year":"2026","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2026.156682_bb0285","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1042\/CS20240833","article-title":"When the liver is in poor condition, so is the heart - cardiac remodelling in MASH mouse models","volume":"138","author":"Bott","year":"2024","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.metabol.2026.156682_bb0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2025.156424","article-title":"Inter-organ crosstalk in health and cardiovascular-renal-hepatic-metabolic disease: a multidisciplinary perspective","volume":"174","author":"Jia","year":"2026","journal-title":"Metabolism"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049526001939?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049526001939?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T08:18:04Z","timestamp":1784708284000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049526001939"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":58,"alternative-id":["S0026049526001939"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2026.156682","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A translational model of MASLD-associated HFpEF defines mitochondrial dysfunction and cardiac plasticity during disease progression and regression","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2026.156682","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"156682"}}